Citations

Clear

4610 citation(s) found for "Lu, Brian".

BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma
Pfitzer, Jeremiah , Chen, Xi , Davis, Zachary, Gyotoku, Kelli, Kumar, Shaji, Ness, Brian G. Van , Petit, Joachim L. , Kumar, Harish , Waliagha, Razan S. , Keeton, Adam B. , Maxuitenko, Yulia Y. , Baughn, Linda B. , Merino, Aimee Marie , Kumar, Shaji , Piazza, Gary Anthony , Ghosh, Taraswi Mitra , Mitra, Amit

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5705-5705

10.1182/blood-2025-5705 Get It

Abstract Multiple myeloma (MM) is the second-most common hematological malignancy in the United States. Myeloma tumors have significant genetic heterogeneity that impacts disease progression and promotes resistance to treatment. RAS is a key oncogenic driver that activates the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K)/AKT pathways..Mutations in genes that code for RAS isozymes, KRAS, HRAS, or NRAS, lead to increased levels of activated GTP-RAS and are associated with the most aggressive forms of cancer. Mutations in the RAS family of genes are most common (40-50%) in myeloma. We and others have reported that RAS mutations may not be disease-initiating but rather arise during disease progression and relapse or as subclonal events that impart selective growth advantage and emerging drug resistance. In addition, non-mutant RAS can also be hyperactivated from upstream signaling (like receptor tyrosine kinases) or loss-of-function mutations in GTPase-activating proteins (GAPs). Given the importance of RAS mutations, allele-specific RAS inhibitors have long been considered an attractive strategy for myeloma treatment. However, multiple studies have reported various mechanisms of resistance to allele-specific RAS inhibitors as well as isoform-specific pan-RAS inhibitors, including newly acquired activating RAS mutations, RAS amplification, unchecked activation of co-expressed wild-type RAS (WT-RAS) isozymes, or acquired bypass mechanisms like new oncogenic fusions. Since MM remains incurable, we sought to improve upon currently available treatments by developing small-molecule inhibitors that preferentially inhibit myeloma cells with activated RAS isozymes. We have created NRasQ61X and KRasG12X mutations by CRISPR-Cas directed edits in a single endogenous RAS allele in human myeloma cell lines (HMCLs) that initially had two wild-type alleles. We found that these mutant-NRAS and mutant-KRAS edited cells have increased proliferation compared to cells with WT-RAS, as well as acquired resistance to several commonly used therapeutics. In this study, we used a triangulation method that combines our drug combination candidate prediction algorithm called ‘secDrug’ and the ‘Direct to Drug’ screening platform that evaluated 84 FDA-approved oncology drugs and emerging therapeutics in these RAS mutant myeloma lines. We identified BIRC5 as a potential target for RAS-mutant myeloma. BIRC5 expression is a key mechanism for the evasion of apoptosis. Notably, oncogenic RAS has been shown to promote MYC stabilization via upregulation of BIRC5. Earlier studies suggested that BIRC5 inhibitors are potent in targeting drug-resistant subclones in hematological malignancies. We performed in vitro cytotoxicity studies and cell-based assays using an in-house panel of HMCLs (n>50) representing WT- and mutant-RAS, as well as innate and acquired response/resistance to the standard of care drugs, proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs), to confirm the potency of novel selective BIRC5 inhibitors, as single agent (IC50 range 0.22-15.30 nM; Mean 4.431±1.041 nM) and in combination with PIs and IMiDs (Chou-Talalay's Combination Index or CI <0.3, indicating strong synergism). Further, we used bulk and single-cell whole-transcriptomics, siRNA-mediated gene knockdown studies, and functional validation to characterize the treatment-induced genes and molecular pathways underpinning the mechanism of action and drug synergy at the subclone level. Finally, we compared the efficacy of these BIRC5 inhibitors against several RAS inhibitors, including cyclorasin B4-27, a bicyclic peptidyl pan-RAS inhibitor, RMC-6236, a multi-selective noncovalent RAS(on) inhibitor, and ADT-007, a novel, highly potent, and selective pan-RAS inhibitor that we have synthesized, and observed comparable effects on cell death and apoptosis. Ex vivo analysis in bone marrow-derived CD138+ cells from myeloma patients using high-throughput Mass Cytometry (CyTOF or Cytometry by Time-Of-Flight) confirmed the dose-dependent reduction of MCL1, Ki-67, CCND1, c-KIT, and MYC. We will present these results that demonstrate the clinical potential of BIRC5 inhibitors as novel candidates in curbing progression and drug resistance in RAS-mutant myeloma.
External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials
Jablonski, Janina , Borchmann, Sven , Upshaw, Jenica , Counsell, Nicholas , Zhu, Cui , Advani, Ranjana H. , André, Marc, Federico, Massimo, Hoppe, Richard T. , Hutchings, Martin , Borchmann, Peter , Advani, Ranjana H , Hoppe, Richard T , Rodday, Angie Mae , Eichenauer, Dennis A. , Tighiouart, Hocine , Hodgson, David , Maurer, Matthew J. , Rossetti, Sára , Cui, Zhu, Hay, Annette E. , Johnson, Peter , Link, Brian K. , Mou, Eric , Savage, Kerry J. , Radford, John , Cerhan, James R. , Evens, Andrew M. , Parsons, Susan K.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1845-1845

10.1182/blood-2025-1845 Get It

Abstract Background: Although progression-free survival (PFS) in early-stage (ES) classic Hodgkin Lymphoma (cHL) is high, there remains a subset of patients (pts) at higher risk of worse outcomes, particularly in those with unfavorable risk disease. Leveraging pt-level data from within the HoLISTIC (Hodgkin Lymphoma International STudy for Individual Care) Consortium, the E-HIPI was developed in clinical trial pts and validated in real-world registry pts to predict 2-year (y) PFS (Rodday. NEJM Evidence 2025). Continuous, objective, and readily measurable pre-treatment variables were considered, with sex, maximum tumor diameter, albumin, and hemoglobin included as significant predictors. Using the E-HIPI, interactive calculators for pt risk, comparison, and stratification were created (https://rtools.mayo.edu/holistic_ehipi/). Although the E-HIPI was developed and validated in both unfavorable and favorable ES cHL pts, the clinical predictors are primarily markers of unfavorable disease. In the development and initial validation cohorts, 2y PFS was 93.7% and 90.3%, respectively, the C-statistic was 0.63 in both cohorts, calibration was strong with slight underprediction of events in the validation cohort, and the E-HIPI outperformed the historic binary classification of patients as favorable or unfavorable using EORTC criteria. However, since pts in the original E-HIPI development and validation were primarily treated with ABVD chemotherapy protocols, additional validation is needed, particularly among pts with unfavorable ES cHL who were treated initially with more intensive chemotherapeutic platforms (e.g., BEACOPP-based). Thus, we conducted an external validation of the E-HIPI in pts treated on recent unfavorable ES cHL GHSG trials. Methods: The validation cohort included 2367 adults (ages 18 to 60y) with newly-diagnosed unfavorable cHL from randomized phase 3 trials conducted by the GHSG (HD14 von Tresckow. JCO 2012; and HD17 Borchmann. Lancet 2021). We calculated the predicted probability of 2y PFS events based on the E-HIPI model equation (scale 1-100%). Model performance was assessed using discrimination and calibration. Discrimination, which is the model's ability to separate high and low risk pts, was assessed using Harrell's C-statistic. Calibration, which is the model's ability to accurately predict absolute risk, was assessed by comparing observed and predicted probabilities of 2y PFS events within quintiles of predicted probabilities and estimating calibration-in-the-large (predicted minus observed event rate) and the calibration slope. Results: For pts treated on unfavorable GHSG trials, mean age was 33y, 95% had stage II disease, mean baseline E-HIPI score (i.e., predicted 2y PFS event rate) was 6.0% (SD=2.3%), and the observed 2y PFS rate was 96.2% (95%CI: 95.4-97.0%). The C-statistic was 0.65 (95% CI: 0.59-0.70), calibration-in-the-large was 0.02, and the calibration slope was 1.08 (95% CI: 0.52, 1.64). Within the lowest risk E-HIPI quintile, the observed 2y PFS event rate was 1.6%, compared with 6.1% in the highest risk quintile. Conclusions: In external validation of the recently published E-HIPI in pts with cHL treated on unfavorable GHSG trials using more intensive BEACOPP-based protocols, discrimination was similar to the original development and validation cohorts. Collectively, the E-HIPI is a treatment-agnostic prediction tool across varied treatment regimens for unfavorable ES cHL pts. Better 2y PFS in the GHSG trials than in the E-HIPI development and initial validation cohorts may have contributed to mild misclassification, likely reflecting differences in treatment regimens. This may be resolved with recalibration or incorporating granular treatment variables into future models. Additional research is needed to understand E-HIPI performance in pts with favorable disease who have even lower event rates as well as to more fully predict individualized pt outcomes across varied chemotherapy platforms and radiation received for all ES cHL pts.
NOTCH pathway activation is mediated by DTX1 loss of function mutations in DLBCL
Dropik, Abigail, Hopper, Melissa, Walker, Janek, Novak, Joseph, Siminski, Miranda, Xianyu, Zilin, Manske, Michelle, Wu, Xiaosheng, Kaplan, Mark, Wenzl, Kerstin, Sarangi, Vivekananda, Maurer, Matthew, Habermann, Thomas, Link, Brian, Chen, Baoyu, Billadeau, Daniel, King, Rebecca, Witzig, Thomas, Ansell, Stephen, Cerhan, James, Novak, Anne, Dropik, Abigail, Hopper, Melissa, Walker, Janek, Novak, Joseph, Siminski, Miranda, Xianyu, Zilin, Manske, Michelle, Wu, Xiaosheng, Kaplan, Mark, Wenzl, Kerstin, Sarangi, Vivekananda, Maurer, Matthew, Habermann, Thomas, Link, Brian, Chen, Baoyu, Billadeau, Daniel, King, Rebecca, Witzig, Thomas, Ansell, Stephen, Cerhan, James, Novak, Anne

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1771-1771

10.1182/blood-2025-1771 Get It

Abstract Diffuse Large B Cell Lymphoma (DLBCL), the most common subtype of aggressive B-cell Non-Hodgkin Lymphoma (NHL), accounts for 30-40% of newly diagnosed NHL cases. Despite recent progress improving our understanding of molecular features of DLBCL, there is still a high relapse rate (~45%) among patients who undergo standard treatment (R-CHOP). Several groups have identified reproducible molecular clusters of DLBCL although, the biologic significance of many of the specific gene mutations within these clusters is poorly understood. DTX1 mutations are a feature of the BN2/C1 DLBCL classifiers and are among the mutations with unknown significance. BN2/C1 DLBCL are a mixture of ABC, GCB, and Unclassified cell of origin (COO) with a common signature being the presence of genetic alterations in genes known to regulate the NOTCH pathway; yet, these tumors lack transcriptional signatures of traditional NOTCH activation, suggesting a unique and undefined biology driven through non-canonical NOTCH pathway activation. DTX1 is an E3 ubiquitin ligase which directly binds the intracellular domain of the NOTCH receptor (NICD), targeting it for degradation, resulting in suppression of NOTCH pathway activity. We therefore hypothesize that DTX1 mutations lead to NOTCH pathway dysregulation and are a critical driver for a subset of BN2/C1 DLBCLs. Using whole exome sequencing (WES) data from 404 newly diagnosed DLBCL patients, we found 8% of patients with mutations in DTX1. Alterations in DTX1 were localized to the NICD binding domain, WWE1. In silico Alphafold modeling of DTX1 WWE1-interaction with NICD revealed that patient mutations clustered within predicted interacting surfaces with NICD. These findings lead to the hypothesis that mutations in the DTX1 WWE1 domain suppress its ability to bind to and degrade NICD, enhancing NOTCH pathway activation in DLBCL. To address this question, we first compared DTX1 protein expression by immunoblot in DTX1 WWE1 mutant (OCI-Ly3 and SUDHL2) and wildtype (WT) (OCI-Ly7, OCI-Ly19, SUDHL6, and U2932) DLBCL cell lines. We found higher expression of NICD1 (p=0.03) in OCI-Ly3 and NICD2 (p<0.0001) in SUDHL2 cell lines compared to WT. This increase was accompanied by an increase in NOTCH surface expression with higher NOTCH1 (p<0.0001) and NOTCH2 (p<0.0001) expression on OCI-Ly3 and SUDHL2 cells, respectively, compared to WT. To remove variability across cell lines we next used CRISPR to generate DTX1 knock out (KO) models using WT DTX1 DLBCL cell lines U2932 and OCI-Ly19. Analysis of NICD and NOTCH receptor protein expression confirmed our initial finding, showing an 8.5 and 4.8-fold increase of NICD1 and a 6 and 2.5-fold increase of NICD2 expression in the U2932 and OCI-Ly19 DTX1 KO cell lines, respectively, compared to empty vector (EV) controls. An increase in surface NOTCH1, and to a lesser extent NOTCH2, was seen in U2932 (p=0.01 and p=0.07, respectively) and OCI-Ly19 (p=0.001 and p=0.2, respectively) KO cells compared to EV controls. To identify pathways affected by DTX1 mutations, we next performed RNAseq on U2932 EV and KO cell lines. Of interest, we did not detect any significant changes in classical NOTCH driven genes (Hes1, Hey1, etc.), supporting prior studies on BN2/C1 tumors. However, we did identify potential non-canonical NOTCH-target genes that may contribute to lymphomagenesis. Gene expression in KO cells showed upregulation of genes involved in germinal center (GC) processes (AICDA, IRF4; p<0.001) and cellular growth and survival (IL6R, CCND2, STAT5B, BCL2; p<0.0001). Measurement of IL6R by flow cytometry and CyclinD2 by immunoblot further verified DTX1-mediated upregulation of IL6R (p<0.01) and CyclinD2 (p<0.01) for U2932 KO cells compared to EV control. We also observed downregulation of genes contributing to cell death (ex. BAX, CASP8, FAS; p<0.05) in KO cells compared to EV. Together, these novel findings support our hypothesis that DTX1 WWE1 mutations lead to dysregulation of the NOTCH pathway by driving overexpression of NICD and NOTCH, resulting in dysregulated expression of proteins involved in cell cycle, GC reaction, and apoptosis. We further provide new biologic insight into BN2/C1 DLBCL, ultimately highlighting a path toward novel therapeutic targets and the advancement of personalized medicine, as patients harboring these mutations may benefit from new therapies targeting inflammatory pathways, such as CELMoDs.
Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective
Brooks, Taylor, Nedved, Adrienne, Wang, Yucai, Grover, Natalie, Yang, XI, Karimi, Yasmin, Schwarz, Tenley, Schwede, Matthew, McKenna, Marshall, Tiger, Yun Kyoung, Abdel-Razeq, Nayef, Moustafa, Muhamad Alhaj, Reinert, Catherine, Major, Ajay, Trotier, Daniel, Pophali, Priyanka, Baron, Kelsey, Hu, Boyu, Jones, Sally, Saha, Aditi, Dave, Nikita, Landsburg, Daniel, Sears-Smith, Megan, Ghosh, Nilanjan, Salafian, Kiarash, Ayers, Emily, Sundaram, Suchitra, Brody, Joshua, Gibson, Alyssa, Kline, Justin, Munoz, Javier, Morales, Rodolfo Garza, Khan, Eiraj, Khan, Cyrus, Castillo, Brenda, Smith, Stephen, Chinyengetere, Fadzai, Dave, Sandeep, Niu, Alex, Hernandez-Ilizaliturri, Francisco, Caimi, Paolo, Hill, Brian, Karimi, Yasmin , Karimi, Yasmin H , Brooks, Taylor, Nedved, Adrienne, Wang, Yucai, Grover, Natalie, Yang, XI, Schwarz, Tenley, Schwede, Matthew, McKenna, Marshall, Tiger, Yun Kyoung, Abdel-Razeq, Nayef, Moustafa, Muhamad Alhaj, Reinert, Catherine, Major, Ajay, Trotier, Daniel, Pophali, Priyanka, Baron, Kelsey, Hu, Boyu, Jones, Sally, Saha, Aditi, Dave, Nikita, Landsburg, Daniel, Sears-Smith, Megan, Ghosh, Nilanjan, Salafian, Kiarash, Ayers, Emily, Sundaram, Suchitra, Brody, Joshua, Gibson, Alyssa, Kline, Justin, Munoz, Javier, Morales, Rodolfo Garza, Khan, Eiraj, Khan, Cyrus, Castillo, Brenda, Smith, Stephen, Chinyengetere, Fadzai, Dave, Sandeep, Niu, Alex, Hernandez-Ilizaliturri, Francisco, Caimi, Paolo, Hill, Brian

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4499-4499

10.1182/blood-2025-4499 Get It

Abstract Introduction: Epcoritamab (epco) and glofitamab (glofit) are bispecific antibodies (BsAbs) approved for the treatment of patients (pts) with relapsed or refractory (r/r) large B-cell lymphomas (LBCLs). Their use is associated with relatively high response rates, with some patients experiencing prolonged remission. It is unclear whether continuous treatment beyond 12 months for pts in remission is beneficial, as continued immunosuppression may result in additional toxicity. We sought to report the outcomes of pts with prolonged remission and survival following BsAb administration. Methods: We performed a multicenter retrospective study including 21 US centers evaluating pts with r/r LBCLs receiving commercially available epco or glofit between 2023 and 2025. Baseline characteristics and outcomes were extracted from medical records. Efficacy and survival outcomes were assessed by site investigators and included overall response rate (ORR), complete and partial response (CR, PR) rates. Pts who responded to BsAbs and had ≥365 days of follow-up from initiation of BsAb treatment were included in the analysis. Results: As of May 15, 2025, a total of 312 pts with r/r LBCLs were treated with BsAbs (epco n=193, glofit n=119) with a median age of 66 years (interquartile range [IQR] 59-73) at BsAb start. Most were male (64.5%), had advanced stage disease (77.4%) and had ECOG performance status of ≤1 (93.3%) at BsAb start. Of 207 pts who had initiated treatment with BsAb ≥12 months prior to data cutoff, we identified 31 pts (15.0%) who had a response to BsAbs (19 epco, 12 glofit) and were alive without progression at 12-months post-BsAb initiation and included them in this landmark analysis. Of the cohort of 19 pts treated with epco, 6 discontinued due to reasons other than disease progression including CAR-T cell therapy (n=2), secondary malignancy (n=2), allogeneic transplant (n=1), or other reasons (n=1). Thirteen of 19 pts received ≥12 months of epco treatment, and, with a median follow-up of 16 months from the start of BsAb, 12 of 13 pts continued receiving epco beyond 12 months with one pt discontinuing after 12 months (observed for an additional 41 days prior to censoring). Of the cohort of 12 pts treated with glofit, 8 pts were observed after completing all planned therapy and 4 patients underwent allogeneic transplant. Among all 31 BsAb-treated patients alive and in remission at 12 months, at the time of data cutoff, 5 pts (12.9%) had progressed (2 previously treated with epco and 3 with glofit). Three of the 4 pts who underwent allogeneic transplant after prior glofit treatment experienced disease relapse. A total of 24 pts (77.4%) were alive at the time of last follow-up, with the causes of death being disease progression (n=1), secondary malignancy (n=1), infection (n=1), and unknown cause (n=4). Conclusions: In this large cohort of r/r LBCL pts treated with BsAbs monotherapy in the standard of care setting, a relatively small proportion of pts (15%) achieve the 12 month PFS landmark. In the absence of robust evidence for what constitutes best practice, different strategies are employed, including continuation of BsAb, observation as well as consolidation with allogeneic transplant or CAR T-cell therapy. Additional follow-up will be reported to help guide clinical decision making regarding the optimal management strategy for this high risk pt population.
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Rein, Lindsay , Boggs, Nathan A. , Yi, Cecilia Y. Arana , Elberink, Hanneke Oude , Radia, Deepti , Reiter, Andreas , Piris‐Villaespesa, Miguel , Dybedal, Ingunn , Panse, Jens , Vachhani, Pankit , Kirshenbaum, Arnold S. , Vaughn, Jennifer E. , Cerquozzi, Sonia , Fahrenholz, John M., Pomares, Helena , Üstün, Celalettin , Herrscher, Richard, Barète, Stéphane , Rivera, Candido E., Vadas, Peter , McCulloch, Derek, Keohane, Clodagh, Schafhausen, Philippe, Pilla, Amanda, Zhang, Jenna, Sun, Lei , Shah, Nisha , Jolin, Hina, Easton, Rachael, Sachs, Jessica, Bose, Prithviraj , Modena, Brian D. , Sabato, Vito , Hartmann, Karin , Akin, Cem , George, Tracy I. , Yi, Cecilia Arana , Oh, Stephen T. , Hunter, Anthony M. , Castells, Mariana , Livideanu, Cristina Bulai , Daele, Paul Van , Álvarez‐Twöse, Iván , Taparia, Minakshi , Mital, Andrzej , Hus, Marek , Romano, Alessandra , Lansigan, Frederick , Papayannidis, Cristina , Rondoni, Michela , Manning, Michael, Guilarte, Mar , Bernstein, Jonathan A. , Elena, Chiara , Orfali, Nina M. , Mannelli, Francesco , Shah, Nisha, Siebenhaar, Frank , DeAngelo, Daniel J.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 80-80

10.1182/blood-2025-80 Get It

Abstract Background: Systemic mastocytosis (SM) comprises a spectrum of subtypes characterized by neoplastic mast cell (MC) infiltration of tissues and release of MC mediators. Non-advanced SM (NonAdvSM), including indolent SM (ISM), smoldering SM (SSM), and bone marrow mastocytosis (BMM) subtypes, is the most prevalent form of SM. NonAdvSM can be associated with debilitating symptomology which can significantly impair quality of life. The gain-of-function somatic KIT c.2447 C>T (p.D816V) mutation is found in up to 95% of patients with SM. Bezuclastinib (CGT9486) is an oral, potent, and selective type 1 tyrosine kinase inhibitor with activity against KIT D816V. Results from Summit (NCT05186753) Part 1 informed the recommended phase 2 dose (100 mg QD bezuclastinib) for Part 2. We report topline results from the 24-week assessment of Summit Part 2. Methods: Summit is a multi-center, randomized, double-blind, placebo (PBO)-controlled Phase 2 trial of bezuclastinib in patients with NonAdvSM who had inadequate symptom control despite best supportive care (BSC) medications. The primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range 0–110), which is a fit-for-purpose patient-reported outcome measure of NonAdvSM symptom severity. Key secondary endpoints included the proportion of patients with ≥50% reduction in serum tryptase, KIT p.D816V variant allele frequency (VAF), bone marrow (BM) MC burden, and MS2D2 TSS, ≥30% TSS reduction. Patients were randomized 2:1 to receive 100mg QD bezuclastinib + BSC or PBO + BSC. Results: As of May 22, 2025, 179 patients were enrolled in Part 2: 119 were randomized to receive bezuclastinib and 60 to placebo. Patients enrolled were representative of the NonAdvSM population with moderate to severe symptoms. Median age (range) was 51 (23-78) years; 65.9% female; mean (SD) baseline MS2D2 TSS 55.6 (19.8); 82% of patients had ISM, 11% had BMM, and 7% had smoldering SSM. At baseline, median (range) KIT p.D816V VAF in whole blood, BM MC burden, and serum tryptase was 0.25% (0-34%), 10% (1-75%), and 40 (6-692) ng/mL, respectively. Bezuclastinib demonstrated statistically significant superiority to placebo on all primary and key secondary endpoints. At Week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean [95% CI] MS2D2 TSS change: –24.3 [–27.6 to –21.1] vs –15.4 [–19.6 to –11.2]; placebo-adjusted difference: –8.9 points; P=0.0002). A ≥50% reduction in serum tryptase was achieved in 87.4% of bezuclastinib-treated patients vs 0% on placebo (P<0.0001). Significantly more patients receiving bezuclastinib achieved ≥50% reductions in KIT D816V VAF, serum tryptase, BM MCs (P<0.0001), MS2D2 TSS (P=0.01), and ≥30% reduction in MS2D2 TSS (P=0.0004). Most treatment-emergent adverse events (TEAEs) were low grade (gr; 70% Gr 1) and reversible. The most common TEAEs (≥10%) in any treatment group and occurring in greater frequency in the bezuclastinib arm were hair color changes (69.5% vs 5.0%), altered taste (23.7% vs 0%), nausea (22.0% vs 13.3%), increased ALT/AST (22.0% vs 6.6%), headache (17.8% vs 11.7%), alopecia (11.9% vs 3.3%), and increased ALP (10.2% vs 3.3%). TEAEs (≥10%) that occurred more often in the placebo group were diarrhea (13% vs 18%), dizziness (10% vs 12%), fatigue (7% vs 12%), and arthralgia (6% vs 15%). ALT/AST elevations ≥Gr 3 were experienced by 5.9% of patients. The only hepatic adverse events (AEs) reported were transient lab abnormalities; none required hospitalization. Treatment-related AEs requiring dose reductions occurred in 11% of patients receiving bezuclastinib. All discontinuations (5.9%) due to treatment-related AEs were due to transaminase elevations; all fully resolved. Conclusions: At 24-weeks, bezuclastinib 100 mg QD demonstrated statistically and clinically significant improvements in symptom burden and biomarkers of disease vs placebo in patients with NonAdvSM. The treatment was generally well-tolerated and effective across a population that is representative of the real-world NonAdvSM population, including SSM. These results support the use of bezuclastinib to reduce SM burden and symptoms in pts with NonAdvSM, and a potentially disease-modifying impact.
Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions
Abbott, Diana, Amorim, Ana , Houshyar, Samin , Adhikari, Arjab, Patel, Dilan A. , Wanjiku, Christopher, Bock, Allison M. , Any, Haya Al, Desai, Nidhi , Gupta, S. C. , Altomare, Nicole , Trotier, Daniel, Ricker, Edd , Hill, Brian T. , Gupta, Supriya , Major, Ajay , Abbott, Diana , Snyder, Jordan Andrew , Ahmed, Nausheen , Villasboas, José C. , Sharp, John, Voorhees, Timothy , Wallace, Danielle, Wagner, Charlotte B , Brooks, Taylor , Tsang, Mazie , Rajab, Mohamed , Iqbal, Madiha , Gupta, Supriya, Karmali, Reem , Pophali, Priyanka A. , Cherng, Hua‐Jay J. , Gupta, Arjun

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1798-1798

10.1182/blood-2025-1798 Get It

Abstract Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective for patients with relapsed/refractory (R/R) follicular lymphoma (FL), but differ in treatment schedules and associated “time toxicity,” or contact days spent physically interacting with the healthcare system. While contact days can be estimated from clinical trials, real-world data provides a more nuanced depiction of treatment-related time burden, which may guide treatment decision-making. The comparative time toxicity of CAR-T vs BsAb in R/R FL is not defined. Methods We conducted a multicenter retrospective study of adults with R/R grade 1-3A FL who received standard-of-care CAR-T (axi-cel, tisa-cel, liso-cel) or BsAb (mosunetuzumab, epcoritamab) in the third-line or later setting before Jan 1, 2025. Time toxicity was defined as outpatient or inpatient days with physical health care system contact, counting multiple visits on the same day as only one day. All days after treatment initiation were counted, regardless of disease progression, therapy completion, or relation to FL therapy. Median contact days over 1-year time horizon were compared, stratified by CAR-T vs BsAb, prior lines of therapy (LOT, 2 vs 3+), and time intervals (0-1, 1-3, 3-6, 6-9, and 9-12 months). Progression-free survival (PFS) and overall survival (OS) were calculated from day of CAR-T infusion or day 1, cycle 1 for BsAb. Cox regression and propensity matching (by age, ECOG, refractory to prior LOT, POD24) were used to assess predictors and survival associations with contact days. Results Among 209 patients from 15 U.S. academic centers, median age was 64, 37% were female, 61% received CAR-T (80% axi-cel, 7% liso-cel, 13% tisa-cel) and 39% BsAb (93% mosun, 7% epcor). Most had Grade 1-2 FL (72%), advanced stage (84%), and extranodal disease (51%). Median prior LOT was 3 (range 2-15), 41% were refractory to prior LOT, and 52% had POD24. Median number of BsAb doses was 10 (range 1-36). Patients receiving BsAb were significantly older (p<.01) and had higher CIRS comorbidity scores (p<.02) in both 2 and 3+ prior LOT cohorts, and had higher ECOG scores (p=.01) and were less likely to be refractory to prior LOT (p=.029) in 3+ LOT cohort. There were no differences in POD24 rates between CAR-T and BsAb. Median PFS for the entire cohort was 3.6 yrs; median OS was not reached. In the 2 prior LOT cohort (N=75), 60% received CAR-T and 40% BsAb. With median follow-up of 1.5 years, median PFS was not reached for CAR-T and 1.6 yrs for BsAb (p<.0001). In the 3+ prior LOT cohort (N=134), 62% received CAR-T and 38% BsAb. With median follow-up of 2 yrs, median PFS was 3.6 yrs for CAR-T and 1.6 yrs for BsAb (p=.0044). In propensity matched analysis, PFS was shorter for BsAb in both 2 LOT (HR 9.0, 95% CI 1.14-71.04, p=.037) and 3+ LOT (HR 3.25, 95% CI 1.06-9.97, p=.039) cohorts as compared to CAR-T. There were no significant differences in OS between CAR-T and BsAb. Median contact days were significantly higher for CAR-T vs BsAb in the 0-1 month interval: 19 vs 8 days in 2 LOT (p<.0001) and 18 vs 7 days in 3+ LOT (p<.0001) cohorts. There were no differences in contact days between CAR-T vs BsAb in subsequent time intervals. Over 1 year, CAR-T had significantly more time toxicity than BsAb: median 51 vs 36 contact days in 2 LOT (p<.0001) and 64 vs 38 days in 3L+ LOT (p<.0001) cohorts; these remained significant in the matched analysis. B symptoms (p=.04) and Grade ≥3 cytopenias (p=.007) were associated with higher contact days in 3+ LOT cohort in univariable analysis. Higher contact days were associated with inferior PFS (HR 1.01, 95% CI 1.00-1.02, p=.032) and OS (HR 1.01, 95% CI 1.00-1.02, p=.038) in 3+ LOT cohort regardless of treatment type. Discussion In this large real-world cohort of patients with R/R FL, CAR-T therapy resulted in better PFS but more time toxicity over the first year as compared to BsAb therapy. Excess time toxicity from CAR-T was driven by more contact days in the first month of treatment. This study provides benchmark data for counseling patients about expected time burden of CAR-T (51-64 days) and BsAb (36-38 days) over the first year of these therapies. Further, with superior PFS of CAR-T in this study and minimal impact of time toxicity on survival outcomes, these data can be used to better support shared decision-making in R/R FL by addressing patient preferences regarding both contact days as well as duration of disease control.
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Rutherford, Sarah C. , Ansell, Stephen M. , Armand, Philippe , Leonard, John P. , Smith, Sonali M. , Timmerman, John M. , Zelenetz, Andrew D. , Gutierrez, Meghan, Béguelin, Wendy , Nadel, Bertrand, Pasqualucci, Laura , LaCasce, Ann S. , Rutherford, Sarah C , Smith, Sonali M , Zelenetz, Andrew D , Béguelin, Wendy , Casulo, Carla , Cerhan, James R , Kridel, Robert , Link, Brian K , Maurer, Matthew , Radtke, Andrea J , Luttwak, Efrat , Salles, Gilles A , Pasqualucci, Laura , LaCasce, Ann Steward , Merryman, Reid W. , Nastoupil, Loretta J. , Casulo, Carla , Cerhan, James R. , Green, Michael Richard , Kahl, Brad S. , Link, Brian K. , Maurer, Matthew J. , Luttwak, Efrat , Salles, Gilles , Sehn, Laurie H.

Mayo Clinic

Blood Advances | December 3, 2025 | Volume: 10 | Issue: 5 | Pages: 1591-1602

10.1182/bloodadvances.2025018079 | PMID 41337699 Get It

Abstract Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation’s biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Group A Streptococcal Pharyngitis: Risk Assessment Using Clinical Scoring Systems in Children and Adults
Linder, Jeffrey A. , Watson, Michael E. , Wessels, Michael R. , Carter, Danielle M, Cohen, Adam L. , Bard, Jennifer Dien , Erdem, Güliz , Gregory, Christopher J. , Mochon, A. Brian, Kaur, Dipleen, Barshak, Miriam B. , Barshak, Miriam B , Kourtis, Athena P. , Martin, Judith M. , Shapiro, Daniel J. , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | December 3, 2025 | Volume: 82 | Issue: Supplement_3 | Pages: i97-i104

10.1093/cid/ciaf668 | PMID 41343363 Get It

Abstract This publication represents the first part of an update to the clinical practice guideline on the diagnosis and management of group A streptococcal (Streptococcus pyogenes or GAS) pharyngitis, developed by the Infectious Diseases Society of America (IDSA). Diagnosis of GAS pharyngitis by clinician judgment alone is unreliable, and unselective testing incurs cost and inconvenience for individuals at low risk of having GAS infection. Clinical scoring systems have been used to quantify the probability of a positive GAS throat culture based on standardized criteria such as the presence of fever; tonsillar enlargement or exudate; tender and enlarged anterior cervical lymph nodes; and the absence of cough. The goal of this article is to determine whether a scoring system should be used to decide which patients should have a diagnostic test performed by rapid antigen detection test, molecular methods, and/or throat culture. We performed a systematic review of randomized and nonrandomized studies that compared the use of a clinical scoring system to clinician judgment alone in predicting the outcome of a throat culture. Evidence from studies in children and adults suggests the diagnostic accuracy of a clinical scoring system is comparable to or slightly higher than clinician judgment alone. However, the studies are limited due to small size, lack of uniformity in outcome measures, and incomplete data. The consensus of the panel is that the balance of benefits and harms favors use of a clinical scoring system as part of the evaluation of patients with sore throat. The principal utility of using a scoring system is to identify patients with low probability of GAS pharyngitis and to reduce unnecessary testing.
Urodynamics in Focus: Applications, Controversies, and Evolving Practices
Linder, Brian J. , Linder, Brian J , Cohn, Joshua A.

Mayo Clinic

Neurourology and Urodynamics | December 3, 2025 | Volume: 45 | Issue: 2 | Pages: 253-253

10.1002/nau.70203 | PMID 41334683 Get It

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Maurer, Matthew J. , Procházka, Vít , Flowers, Christopher R. , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot, Fournier, Marguerite , Larson, Melissa C. , Dietrich, Caroline E. , Ghesquières, Hervé , Gandhi, Maher K. , Cheah, Chan Y. , Hawkes, Eliza A. , Seymour, John F. , Freeman, Ciara L. , Friedberg, Jonathan W. , Casulo, Carla , Móciková, Heidi , Fürst, Tomáš, Feugier, Pierre, Tilly, Hervé , Davies, Andrew , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Smedby, Karin E. , Prochazka, Vit , Flowers, Christopher R , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot J, Fournier, Marguerite , Larson, Melissa C , Dietrich, Caroline E , Kridel, Robert , Gandhi, Maher K , Cheah, Chan Yoon , Hawkes, Eliza , Seymour, John F , Clausen, Michael Roost , Casulo, Carla , Habermann, Thomas , Wang, Yucai , Nastoupil, Loretta J , de Nully Brown, Peter , Janikova, Andrea , Tilly, Hervé , Davies, Andrew , Cartron, Guillaume , Burack, W Richard , Chihara, Dai , Martin, Peter , Cohen, Jonathon B , Lossos, Izidore S , Kahl, Brad S , Sehn, Laurie H , E Smedby, Karin , Salles, Gilles A , Trnĕný, Marek , Link, Brian K , Morschhauser, Franck , Cerhan, James R , Maurer, Matthew , El‐Galaly, Tarec Christoffer , Jakobsen, Lasse Hjort , Clausen, Michael Roost , Wahlin, Björn , Casulo, Carla , Habermann, Thomas M. , Wang, Yucai , Nastoupil, Loretta J. , Brown, Peter de Nully , Belada, David , Feugier, Pierre , Haïoun, Corinne , Burack, Richard , Chihara, Dai , Kahl, Brad S. , Sehn, Laurie H. , Salles, Gilles , Trněný, Marek , Link, Brian K. , Morschhauser, Franck , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | December 2, 2025 | Volume: 44 | Issue: 2 | Pages: 117-128

10.1200/jco-25-00892 | PMID 41329901 Get It

PURPOSE Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074). RESULTS The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL. CONCLUSION The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.